Skip to main content
Equibles
RARE $15.22 +3.19%
RARE logo
RARE · Ultragenyx Pharmaceutical Inc.
Track RARE — free

Use RARE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RARE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.22 +0.47 (+3.19%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$1.43B
Shares
98.59M
Volume · Oct 2 3.88M Avg daily vol (3M) 3.75M
All webcasts

Earnings call · FY2026 Q2

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call

Concluded Aug 4, 2026
Aug 4, 2026 0 turns
Period
FY2026 Q2
Runtime
—
Sources
3 artifacts
Slides 8 8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. slides, 8-K earnings release, 10-Q stay in one workspace.

Angelman syndrome Phase III (GTX102) endpoints and design 10 DTX401 regulatory progress 5 UX143 (citruzumab) for osteogenesis imperfecta 5 GTS1-2 Phase III ASPIRE readout 4 Long-term GTX102 durability and safety 4 UX111 regulatory progress 4

Management tone

Positive

Net tone +35 · moderate hedging

Grounding quotes
  • “The Phase I to open-label single-arm data demonstrates substantial clinical benefit, well beyond what might be considered with placebo”
  • “While neither study hit statistical significance for the primary endpoints of annualized fracture reductions, we did see clear signals of biologic activity”
  • “We will see the data when they come.”

Forward guidance

3 guided metrics

Management's latest ranges and targets are included below.

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Revenue $214.00M +28.1% YoY
Diluted EPS -$0.90
Net income -$92.00M

Research materials

Open the source you need; every reader stays inside this workspace.

Presentation 8 pages 8-K earnings release Filed Aug 4, 2026 10-Q report Filed Aug 5, 2026 Company webcastOpen the original investor-relations page

Forward guidance

From the 8-K filed Aug 4, 2026.

Metric Guided
Total revenue Initiated
full year 2026
 $730M – $760M
Crysvita revenue Initiated
full year 2026
 $500M – $520M
Dojolvi revenue Initiated
full year 2026
 $100M – $110M

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Product$112.00M +38.3% YoY
Royalty$102.00M +18.6% YoY
Full-screen source Call document

RARE transcript alerts

Ultragenyx Pharmaceutical Inc.

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →